Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
Details
The document's own metadata, straight from the source system.
- Title
- Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
- Posted
- May 22, 2026
- Comment period
- May 22, 2026 – Jun 18, 2026
- FR Doc
- 2026-10321
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Choose up to five.
| Organization | Vaccine updates and accessibility |
|---|
1 organization-typed comment could not be identified.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jun 14, 2026Comment from Grillo TheresaSupportIndividual
The commenter supports the development and use of mRNA influenza vaccines, specifically highlighting Moderna's mRNA-1010. They argue that mRNA technology allows for faster production and better antigenic matches, which are crucial for protecting high-risk populations like older adults.
Read comment → - May 24, 2026Comment from Brooke OroszSupportIndividualRead comment →